heart failure with reduced ejection fractionEMPA-REG OUTCOMEempagliflozintype 2 diabetes mellitus.Background In the EMPA-REG OUTCOME trial, ejection fraction (EF) data were not collected. In the subpopulation with heart failure (HF), we applied a new predictive model for EF to determine the ...
Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-2486. doi:10.1016/j.jacc.2017.08.074 PubMedGoogle ScholarCrossref 3. Lewis EF, Lamas GA, O’Meara E, et al; CHARM Investigators. ...
Impact of Empagliflozin on Central Cardiac Hemodynamics in Heart Failure With Reduced Ejection Fraction PCWP was significantly reduced (−2.40 mm Hg; 95% confidence interval: −3.96 to −0.84 mm Hg; p = 0.003) but not CI (−0.09 l/min/m2; 95% confidence interval: −0.14 to 0.32 ...
METHODS: In the EMPEROR-Reduced (Empagliflozin Outcome T rials in Chronic Heart Failure With Reduced Ejection Fraction) and EMPEROR-Preserved (Empagliflozin Outcome T rials in Chronic Heart Failure With Preserved Ejection Fraction) t...
Importantly, the effects of both drugs were also present in the control samples (not stimulated with GLUC or AII), demonstrating the occurence of oxidative stress in overweight patients with all spectrum of heart failure (reduced, mildly reduced, and preserved ejection fraction), thus, strongly sup...
How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? KEY FINDING. The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions...
2C) values were slightly, but significantly reduced in both diabetic (EF 42.8 ± 4.0%, FS 21.8 ± 1.4%) and hypersensitive rats (EF 39.2 ± 2.7%, FS 15.4 ± 1.8%) compared to SD rats (EF 60.1 ± 2.1%, FS 31.9 ± 1.4%). Systolic heart ...
HEART failure patientsMARKOV processesVENTRICULAR ejection fractionCOST estimatesIntroduction: Empagliflozin demonstrates promising clinical benefits in patients with heart failure (HF). While an early study demonstrates that empagliflozin is cost-effective for treating HF patients with re...
Together, our data show for the first time that empagliflozin treatment of nondiabetic mice with reduced EF heart failure blunts the progressive decline in cardiac function both in vivo and ex vivo. Interestingly, although SGLT1 mRNA is abundantly expressed in the human heart as well as in other...
HF heart failure HFpEF heart failure with preserved ejection fraction HFrEF heart failure with reduced ejection fraction LV left ventricular SGLT2i sodium-glucose−linked co-transporter-2 inhibitor UNX uninephrectomy Despite significant advances in cardiovascular diagnostics and therapeutics, heart failure ...